Tests XW003 injections in adults with obesity and sleep apnea
Tests XW003 injections against placebo in adults with obesity and sleep apnea.
Plain-language title generated from the registry record
Registry title: A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity and obstructive sleep apnea who do not use positive airway pressure (PAP) therapy.
- Age
- 18 Years to 75 Years
- Sex
- All sexes can join.
- Disease stage
- Obstructive sleep apnea confirmed by a sleep study (PSG) with an AHI of 15 or more, and a BMI of 28.0 kg/m2 or more.
- Earlier treatment
- No PAP use for at least 4 weeks before screening and none during the study. At least 1 self-reported unsuccessful diet attempt to lose weight. No weight-loss or blood-sugar-lowering medicine in the 3 months before screening.
- Biomarker or test result
- HbA1c below 6.5% (48 mmol/mol) at screening. Fasting blood glucose below 7.0 mmol/L (126 mg/dL), and 2-hour glucose below 11.1 mmol/L (200 mg/dL) after an oral glucose tolerance test.
Main reasons for not taking part
- Diabetes (except gestational diabetes)
- Central or mixed sleep apnea with 50% or more central or mixed events, or Cheyne Stokes breathing
- Obesity hypoventilation syndrome or high carbon dioxide in the blood during the day
- Weight change of more than 5% in the 3 months before screening
- Past or planned surgery for obesity (liposuction or abdominoplasty more than 1 year before screening is allowed)
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07387094, who can take part
Where in China
- Peking University People's HospitalBeijing, ChinaContact: Linong Ji, DrTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Hangzhou Sciwind Biosciences Co., Ltd.
- Trial code
- NCT07387094
- Record updated
- 28 August 2026
- Original description
The aim of the study is to assess the efficacy and safety of XW003 injections in obese participants with OSA but not receiving PAPRead full original descriptionShow less
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy and Safety of XW003 Injections in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy
The aim of the study is to assess the efficacy and safety of XW003 injections in obese participants with OSA but not receiving PAP
Inclusion: Body mass index (BMI) ≥ 28.0 kg/m2; The results of PSG meet the diagnosis criteria of OSA and with an AHI ≥15 at screening; Participants must not have used PAP for at least 4 weeks prior to screening and not use PAP during the study; Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.
Exclusion: Change of body weight >5% within 3 months prior to screening (self-reported); Have a prior or planned surgical treatment for obesity (except liposuction or abdominoplasty if performed more than 1 year prior to screening); History of endocrine disorders which have significant impact on body weight; Diagnosis of diabetes (except gestational diabetes), ketoacidosis or hypertonic state/coma; Respiratory and neuromuscular diseases that could interfere with the results of the trial; Diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia; HbA1c ≥6.5% at screening; Fasting blood glucose ≥7.0 mmol/L or 2-hour blood glucose ≥11.1 mmol/L after oral glucose tolerance test (OGTT) at screening; participants with FBG ≥6.1 mmol/L but <7.0 mmol/L require OGTT; Have received any medication for body weight loss and blood glucose lowering or medication that could lead to significant body weight increase, within 3 months prior to screening; Have diagnosis of Cheyne Stokes Respiration, or diagnosis of Central or Mixed Sleep Apnea with % of mixed or central apneas/hypopneas ≥50%.